SRC and breast carcinoma: Although it lacks binding specificity to a particular G4, it is thought to constitute a suitable model for such a proof‐of‐concept study.[30] For instance, R. Rodriguez et al used PDS to reduce SRC proto‐oncogene expression in human breast cancer cells and validated SRC‐G4 as a druggable target.[31] In addition, we also aimed to elucidate the binding mechanism as an effort to guide the design of better ligands for this special G4 structure in the future work.